Physician profile
Kim T Bui
NPI 1235244252
$4,211.49
in general payments reported to CMS, 2019-2025
33 companies · $423 in 2025
The $423 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $289 · 2021: $654 · 2022: $1,591 · 2023: $334 · 2024: $299 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $1,133.85 | 2022 | |
| Abbvie INC. | $349.05 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $308.74 | 2021-2025 | |
| Astellas Pharma US INC | $273.74 | 2019-2025 | Veozah |
| Daiichi Sankyo INC. | $201.51 | 2020-2022 | |
| Therapeuticsmd, INC. | $198.48 | 2019-2022 | |
| Allergan, INC. | $190.05 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.09 | 2019-2024 | |
| Exeltis, USA INC. | $158.53 | 2019-2023 | Slynd |
| Aspira Women'S Health INC | $153.57 | 2020-2024 | Ova1 |
| Organon LLC | $113.48 | 2022-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $106.76 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Amgen INC. | $91.63 | 2021-2025 | Evenity, Prolia, Prolia |
| Coopersurgical, INC. | $78.91 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Avion Pharmaceuticals | $70.66 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $66.08 | 2022-2024 | Accrufer |
| Vertical Pharmaceuticals, LLC | $62.37 | 2019 | |
| Pfizer INC. | $57.69 | 2024-2025 | |
| Myovant Sciences INC. | $53.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $51.10 | 2019-2020 | |
| Exact Sciences Corporation | $48.91 | 2023-2025 | Cologuard Collection Kit |
| Biogen, INC. | $47.55 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $38.10 | 2021 | |
| Ethicon US, LLC | $32.15 | 2025 | Evarrest, Stratafix |
| Sumitomo Pharma America, INC. | $27.81 | 2023 | Myfembree |
| Lilly USA, LLC | $25.55 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.85 | 2022 | |
| Mission Pharmacal Company | $15.83 | 2019 | |
| Duchesnay USA Incorporated | $14.92 | 2019 | |
| Innovation Technologies INC | $13.74 | 2025 | Irrisept |
| Minerva Surgical, INC | $13.70 | 2019 | |
| Lupin INC. | $13.55 | 2019 | |
| Channel Medsystems, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.